Global Non-invasive Prenatal Testing Market Outlook to 2026

DUBLIN, August 25, 2021 / PRNewswire / – The report, “Non-invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunities, and Forecast 2021-2026” has been added to ResearchAndMarkets.com offer.

Research and Markets logo

The global non-invasive prenatal testing market has shown strong growth in the period 2015-2020. The non-invasive prenatal test (NPNI) is a form of prenatal screening performed on a blood sample from a pregnant woman to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing fragments of DNA in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.

One of the key factors driving the growth of the market is the increasing prevalence of fetal genetic disorders. In addition, technological advancements in life sciences and healthcare industry are also driving the market. For example, the development of DNA sequencing technologies, regenerative drugs, and breakthroughs in molecular research have created immense opportunities to combat the risks of any serious disease in the early stages itself. In addition, the increasing acceptance rate of prenatal testing, along with the growing health awareness and awareness of the benefits and importance of these tests among the masses, is also driving the growth of the market.

Healthcare providers, as well as expectant parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate and sickle cell disease, and treat them in the early stages of fetal development. Moreover, the tendency to procreation at a high maternal age (35 years or older) is also positively impacting the growth of the market. Advancing maternal age can lead to many health complications, such as high blood pressure, reduced fertility, risk of miscarriage, and increased risk of chromosomal abnormalities in the fetus. Looking ahead, the publisher expects the global non-invasive prenatal testing market to grow at a CAGR of 10.70% during the period 2021-2026.

Competitive landscape:

The report also analyzed the competitive landscape of the market with some of the major key players of non-invasive prenatal testing companies being Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive summary

4 Presentation
4.1 Overview
4.2 Key Industry Trends

5 Global Non-invasive Prenatal Testing Market
5.1 Market overview
5.2 Market performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market breakdown by product type
6.1 Consumables
6.1.1 Market trends
6.1.2 Market Forecast
6.2 Devices
6.2.1 Market trends
6.2.2 Market Forecast

7 Market breakdown by type of test
7.1 Maternity 21
7.1.1 Market trends
7.1.2 Market Forecast
7.2 Harmony
7.2.1 Market trends
7.2.2 Market Forecast
7.3 Panorama
7.3.1 Market trends
7.3.2 Market Forecast
7.4 Verification
7.4.1 Market trends
7.4.2 Market Forecast
7.5 SUPERB
7.5.1 Market trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market trends
7.6.2 Market Forecast

8 Market breakdown by technology
8.1 NGS
8.1.1 Market trends
8.1.2 Market Forecast
8.2 WGS
8.2.1 Market trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market trends
8.3.2 Market Forecast

9 Market breakdown by method
9.1 Ultrasonic detection
9.1.1 Market trends
9.1.2 Market Forecast
9.2 Biochemical screening tests
9.2.1 Market trends
9.2.2 Market Forecast
9.3 Cell-free DNA in maternal plasma tests
9.3.1 Market trends
9.3.2 Market Forecast
9.4 Fetal cells in maternal blood tests
9.4.1 Market trends
9.4.2 Market Forecast
9.5 Other tests
9.5.1 Market trends
9.5.2 Market Forecast

10 Market Split by Application
10.1 Trisomy
10.1.1 Market trends
10.1.2 Market Forecast
10.2 Microdeletion syndrome
10.2.1 Market trends
10.2.2 Market Forecast
10.3 Others
10.3.1 Market trends
10.3.2 Market Forecast

11 Market breakdown by end user
11.1 Hospitals
11.1.1 Market trends
11.1.2 Market Forecast
11.2 Diagnostic laboratories
11.2.1 Market trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market trends
11.3.2 Market Forecast

12 Market breakdown by region

13 SWOT Analysis

14 Value chain analysis

Analysis of the five forces of 15 carriers

16 Competitive landscape
16.1 Market structure
16.2 Key players
16.3 Profiles of key players
16.3.1 Agilent Technologies, Inc.
16.3.1.1 Company presentation
16.3.1.2 Product portfolio
16.3.1.3 Financial data
16.3.1.4 SWOT Analysis
16.3.2 Berry Genetics, Inc.
16.3.2.1 Company presentation
16.3.2.2 Product portfolio
16.3.3 BGI Genomics Co., Ltd.
16.3.3.1 Company overview
16.3.3.2 Product portfolio
16.3.3.3 Finances
16.3.4 Eurofins LifeCodexx GmbH
16.3.4.1 Company overview
16.3.4.2 Product portfolio
16.3.4.3 Finances
16.3.5 F. Hoffmann-La Roche SA
16.3.5.1 Company overview
16.3.5.2 Product portfolio
16.3.5.3 SWOT Analysis
16.3.6 GE Healthcare
16.3.6.1 Company overview
16.3.6.2 Product portfolio
16.3.7 Igenomix
16.3.7.1 Company. Overview
16.3.7.2 Product portfolio
16.3.7.3 Finances
16.3.8 Illumina, Inc.
16.3.8.1 Company overview
16.3.8.2 Product portfolio
16.3.8.3 Finances
16.3.8.4 SWOT Analysis
16.3.9 Laboratory company
16.3.9.1 Company overview
16.3.9.2 Product portfolio
16.3.9.3 Finances
16.3.9.4 SWOT Analysis
16.3.10 Natera, Inc.
16.3.10.1 Company presentation
16.3.10.2 Product portfolio
16.3.10.3 Finances
16.3.11 Perkinelmer, Inc.
16.3.11.1 Company presentation
16.3.11.2 Product portfolio
16.3.11.3 Finances
16.3.11.4 SWOT Analysis
16.3.12 Thermo Fisher Scientific Inc.
16.3.12.1 Company presentation
16.3.12.2 Product portfolio
16.3.12.3 Finances
16.3.12.4 SWOT Analysis
16.3.13 Yourgene Health
16.3.13.1 Company presentation
16.3.13.2 Product portfolio
16.3.13.3 Finances

For more information on this report, visit https://www.researchandmarkets.com/r/oeo3wo

Media contact:
Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

Cision

Cision

View original content: https://www.prnewswire.com/news-releases/outlook-on-the-non-invasive-prenatal-testing-global-market-to-2026—by-product-type-test – type-technology-method-application-end-user-and-region-301362674.html

SOURCE Research and Markets

Comments are closed.